Erasca's mission is to erase cancer, specifically targeting RAS-driven cancers, and while we are making progress, we still have a long way to go.

In the current environment, the focus should be on developing products that can demonstrate clear impact on patients, whether through safety or efficacy.

When we went public in 2021, we decided to save our funds instead of spending them immediately, anticipating tougher days ahead in the biotech landscape.

After facing significant setbacks, we took back control from our investors and focused on learning from our mistakes to develop a better product.

We decided that 100% of every donation would directly fund medical care, and we would be completely transparent about our financials and operations.

Despite the challenges, we learned to allocate capital better and operate more efficiently, which allowed us to grow significantly even in tough times.

During the pandemic, we faced significant challenges, but we emerged stronger. We learned to focus on efficiency and maintain a startup mentality, which helped us navigate the crisis successfully.

Since launching Watsi, over 10,000 donors have funded healthcare for 4,000 patients across 20 countries, raising over $3.5 million, all of which has gone directly to those in need.

Our goal is to empower patients by consolidating their healthcare data into one accessible platform, improving their experience and potentially reducing costs over time.